• Home
• dual closure
• First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

4.5 (382) · $ 21.50 · In stock

Results from the SWISS-APERO Trial reported at TCT 2021 and published simultaneously in Circulation

Left atrial appendage sealing performance of the Amplatzer Amulet and Watchman FLX device

Left Atrial Appendage Closure: An Update - Cardiac Interventions Today

Intracardiac Echocardiography-Guided Left Atrial Appendage Closure With a Novel Foam-Based Conformable Device: Safety and 1-Year Outcomes - ScienceDirect

Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option

Current Endocardial Approaches for LAA Closure – touchCARDIO

Profile comparison between WATCHMAN 2.5 (A) and WATCHMAN FLX (B).

With Amulet or Watchman, 50% of patients still leak either way

TCT DAIC

JCM, Free Full-Text

Meta-Analysis of WATCHMAN FLX™ Device vs Amplatzer™ Amulet™ Occluder

Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion

WATCHMAN versus ACP or Amulet devices for left atrial appendage occlusion: a sub-analysis of the multicentre LAARGE registry

Left Atrial Appendage (LAA) Occluders